Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
71
resultados
Última actualización
26/04/2026 [06:45:00]
Resultados 25 a 50 de 71
Resumen de: US20260102397A1
The present invention relates to a pharmaceutical composition for the treatment of leukemia comprising an FMS-like tyrosine kinase-3 (FLT3) inhibitor and a pharmaceutically acceptable excipient.
Resumen de: AU2024380949A1
The present invention relates to a method of treating an anaplastic lymphoma kinase (ALK) fusion-positive solid tumour or central nervous system tumour, comprising administering to a subject in need of such treatment a therapeutically effective amount of alectinib, or a pharmaceutically acceptable salt thereof, wherein the subject is aged <18 years.
Resumen de: US20260103445A1
The present invention relates to compositions comprising an RXR agonist, an RAR agonist, or a dual RXR/RAR agonist. The present invention further relates to methods of using the agonist compositions for treating or preventing dementia and cancer. In some embodiments, the dementia comprises Alzheimer's disease. In some embodiments, the cancer comprises leukemia.
Resumen de: US20260103537A1
Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.
Resumen de: US20260102374A1
Methods of treating bacterial infection in immunocompromised subjects and subjects with one or more underlying malignancies include administering a combination of meropenem and vaborbactam to the subject. Suitable subjects to be treated can include a subject with a history of ongoing leukemia or lymphoma, a subject that has had an organ transplant, stem cell transplant, bone marrow transplant, or splenectomy, a subject receiving immunosuppressive medications, a subject receiving bone marrow ablative chemotherapy, a subject with neutropenia and subject suffering from or having suffered from a malignancy.
Resumen de: AU2024353668A1
Described herein are Casitas B-lineage lymphoma (Cbl) inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of a disease or condition associated with Cbl-b activity, such as cancers.
Resumen de: AU2024350024A1
Provided herein are systems, kits, and methods for generating an enriched T cell population from an initial peripheral blood mononuclear cell (PBMC) population using at least two types of cell-binding reagents: (e.g., particles conjugated to CD32, CD19, CD244, or CD25 binding agents), where the enriched T cell population is: i) enriched for desired T-cells (e.g., early memory T cells and naïve T cells), and ii) depleted in normal and malignant non-desired cells selected from: CD25hi regulatory T-cells (Tregs), CD25hi CLL cells, CD244 T-cells, CD32+ monocytes, CD32+ myeloid leukemia cells, CD32 basophils, CD19+ and/or CD32+ B cells, CD244+ natural killer (NK) cells, and myeloid cells). In certain embodiments, the enriched T cell populations are used for generating a population of chimeric antigen receptor (CAR) T-cells, T-cell receptor-engineered T cells, or Tumor-infiltrating T lymphocyte (ITL) products.
Resumen de: AU2024369003A1
The present application relates to use of a hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI) in rare anemia. Specifically disclosed in the present application is use of certain hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) in the treatment of anemia of myelodysplastic syndromes (MDS anemia), beta-thalassemia (β-thalassemia), and/or sickle cell disease (sickle cell anemia, SCD anemia).
Resumen de: US20260103515A1
The present disclosure relates to doses and dosing regimens of a bispecific antibody that binds myeloid cell surface antigen CD33, and the Vδ2 chain of the human Vγ9Vδ2 T cell receptor; to pharmaceutical compositions comprising said antibodies, as well as methods of administration of the referred doses, and to the use of said antibodies in the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Neoplasms (MDS), in particular Relapsed or Refractory (R/R) AML or MDS.
Resumen de: AU2024366453A1
The present invention relates to methods of treating previously untreated diffuse Large B-Cell Lymphoma (DLBCL) defined as high risk by Circulating Tumor DNA (ctDNA), by administering glofitamab and in combination with chemotherapy.
Resumen de: WO2026078067A1
The present disclosure relates to human/cynomolgus cross-reactive antibody arms that bind specifically to FcRH5, which preferentially bind to membrane-bound FcRH5 (isoform c) and which do not cross-react with other FcRH family members. The present disclosure relates to bispecific antibodies which bind to human FcRH5 using the anti-FcRH5 arms described herein and bind to human CD28. The bispecific antibodies of the disclosure provide FcRH5-dependent costimulatory signal to T cells, even in the presence of soluble FcRH5, enhancing T cell mediated anti-tumor immunity against FcRH5-expressing cancers such as multiple myeloma.
Resumen de: WO2026078266A1
The present invention refers to anti-BCMA specific single domain antibodies, and their use in chimeric antigen receptor cells, specifically T cells, which are of use in the treatment of cancer characterized by an increase in cells expressing BCMA, in particular multiple myeloma.
Resumen de: US20260104330A1
The present invention discloses a leukemia cell separation and extraction device, comprising a sampling tube and a filtration assembly. Top end of inner wall of sampling tube is equipped with multiple limit blocks, while filtration assembly includes a retaining ring installed at top opening of the sampling tube, with one side contacting the limit blocks. The bottom end of inner wall of retaining ring is connected to an air duct via multiple connecting plates, with membranes between each plate. Main drainage rods, inclined and circumferentially arranged, connect the air duct's outer wall to the retaining ring's inner wall, with zigzag secondary drainage rods between them. One end of the retaining ring is attached to a push plate, and a collecting assembly is mounted on the air duct. This configuration allows for efficient plasma extraction from blood samples, retaining blood cells in the original container and enhancing separation efficiency.
Resumen de: WO2026078018A1
The present invention refers to anti-CD33 specific single domain antibodies, and their use in chimeric antigen receptor cells, mainly T cells, which are of use in the treatment of cancer characterized by an increase in cells expressing CD33, in particular acute myeloid leukemia.
Resumen de: WO2024254455A1
The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of lymphoma (e.g., a diffuse large B-cell lymphoma (e.g., a germinal-center B-cell- like or activated B-cell-like diffuse large B-cell lymphoma). The invention is based, at least in part, on the discovery that macrophage biomarkers are useful in methods of identifying, diagnosing, or predicting the therapeutic efficacy of treatment with an anti-CD79b immunoconjugate (e.g., polatuzumab vedotin) and an anti-CD20 antibody (e.g., obinutuzumab or rituximab).
Resumen de: GB2644560A
Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.
Resumen de: EP4726031A1
This disclosure discloses a CLL1-CAR-T cell, as well as their preparation methods and applications. Specifically, it reveals CLL1-CAR-T cell that contain a chimeric antigen receptor, which comprises a single-domain antibody, a hinge region, a transmembrane region, and an intracellular signaling region. The amino acid sequence of the single-domain antibody corresponds to positions 22-150 of SEQ ID No.1. The CLL1-VHH-1 CAR-T cells of this disclosure can effectively secrete the T-cell-specific effector molecule IFN-γ, specifically and efficiently kill CLL1+ target cells, and exhibit favorable in vivo anti-tumor activity. They not only significantly inhibit the proliferation of tumor cells in mice but also markedly prolong the survival time of mice. The CLL1-VHH-1 CAR-T cells of this disclosure demonstrate excellent anti-tumor capabilities and can be used for immunotherapy of diseases related to the CLL1 target, such as acute myeloid leukemia, presenting broad prospects for clinical applications.
Resumen de: AU2026202107A1
The presently disclosed subject matter provides methods and compositions for treating myeloid disorders (e.g., acute myeloid leukemia (AML)). It relates to immunoresponsive cells bearing antigen recognizing receptors (e.g., chimeric antigen receptors (CARs)) targeting AML-specific antigens. 5 ar a r
Resumen de: AU2024339935A1
The invention relates to a modified immune cells for use in the treatment of a solid tumor in a subject, wherein the modified immune cell comprises one or more exogenous nucleic acid molecules encoding a transgenic construct targeting an antigen expressed in a cancerous cell of said solid tumor, in said immune cell, Nuclear Receptor Subfamily 2 Group F Member 6 (NR2F6) activity is inhibited (in comparison to a control immune cell), and binding of the immune cell to the antigen is associated with death of said cancerous cell expressing the antigen, and inducing a secondary immune reaction in the subject against cancerous cells of the solid tumor, wherein said secondary immune reaction is non-specific to the antigen targeted by the transgenic construct (epitope spreading). The invention relates further to a modified immune cell comprising one or more exogenous nucleic acid molecules encoding a transgenic construct targeting an antigen expressed in a cancerous cell of a solid tumor, wherein in said cell, NR2F6 activity and Casitas B-lineage lymphoma proto-oncogene-b (CBLB) activity is inhibited (compared to a control immune cell). The invention relates further to a pharmaceutical composition comprising the modified immune, suitable for the treatment of a solid tumor, comprising additionally a pharmaceutically acceptable carrier, and to an in vitro method for enhancing the cytolytic activity of a modified immune cell.
Resumen de: WO2026076363A1
Provided herein is the use of particular dose levels or amounts of certain pyruvate kinase activators or pharmaceutically acceptable salts or compositions thereof, for treating anemia associated with low risk MDS, lower risk MDS and/or intermediate risk MDS (collectively, LRMDS) and other conditions.
Resumen de: WO2026074291A1
The invention relates to immunotherapy, and to invariant natural killer T (iNKT) cells, and iNKT cell immunotherapy. The invention concerns CAR-iNKT cell immunotherapy, in particular, mono- and bi-specific CAR-iNKT cell immunotherapy, as well as pharmaceutical compositions comprising these iNKT cells, and to their use in therapy, as well as therapies and methods for treating, preventing, or ameliorating cancer or infection. The invention also concerns the treatment of various leukaemias, such as acute lymphoblastic leukaemia (ALL), including infant ALL.
Resumen de: WO2026074142A1
OF THE INVENTION USE OF INHIBITORS OF THE N-ACETYLASPARTATE SYNTHETASE FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIAS Acute Myeloid Leukemias (AML) are characterized by the proliferation of immature blood cells, leading to suppression of normal hematopoiesis. Despite existing treatments, resistance and relapse are common. A metabolomic analysis revealed increased N-Acetyl-Aspartate (NAA) levels in leukemic cells compared to normal HSCs, with high NAA levels linked to poor prognosis. The inventors studied the gene NAT8L, responsible for NAA synthesis, and found correlations with patient survival. Using CRISPR-cas9, the inventors targeted NAT8L in AML cell lines and observed that NAA depletion improved response to treatments and increased survival in vivo. Inhibiting NAA synthetase thus represents a therapeutic strategy to enhance chemotherapy efficacy and prevent relapse in AML patients.
Resumen de: WO2026075450A1
The present invention relates to a method for assessing disease severity or a clinical stage of, or predicting prognosis for chemotherapy in, dogs suffering from lymphoma. According to the present invention, in dogs suffering from lymphoma, it has been confirmed that CD34-positive expression is associated with a higher risk of cranial mediastinal lymph node metastasis and fever compared to CD34-negative expression; and since the CD34-positive expression is classifiable as a clinical disease within the WHO clinical substages, CD34 positivity can serve as an indicator of poor prognosis. In addition, it has been confirmed that MHC class II (MHCII)-positive expression is associated with a higher risk of fever and adverse effects from chemotherapy compared to MHCII-negative expression, and thus can serve as an indicator of favorable prognosis. Accordingly, the present invention may contribute not only to preserving companion dog health and reducing medical expenses for pet owners, but also to improving the quality of veterinary consultations.
Resumen de: US20260097122A1
The present disclosure relates to CD19/22 CAR T-cell products and methods for treating high risk or relapsed CD19+ or CD22+ haematological malignancies.
Nº publicación: US20260098097A1 09/04/2026
Solicitante:
THE REGENTS OF THE UNIV OF COLORADO A BODY CORPORATE [US]
Resumen de: US20260098097A1
0000 Methods of treating various types of cancer, including cutaneous T-cell lymphoma, involve administering a therapeutically effective amount of a pharmaceutical composition containing a genetically engineered C-C motif chemokine receptor 4 bispecific immunotoxin, alone, or in combination with one or more additional therapeutic agents, such as a pharmaceutical composition containing an antibody-drug conjugate.
BOPI
Sede Electrónica
